Mass treatment to eliminate filariasis in Papua New Guinea

被引:109
|
作者
Bockarie, MJ
Tisch, DJ
Kastens, W
Alexander, NDE
Dimber, Z
Bockarie, F
Ibam, E
Alpers, MP
Kazura, JW
机构
[1] Case Western Reserve Univ, Sch Med, Div Geog Med, Cleveland, OH 44106 USA
[2] Case Western Reserve Univ, Sch Med, Ctr Int Hlth, Cleveland, OH 44106 USA
[3] Univ Hosp Cleveland, Cleveland, OH 44106 USA
[4] Papua New Guinea Inst Med Res, Goroka, Papua N Guinea
[5] London Sch Hyg & Trop Med, London WC1, England
[6] Curtin Univ, Ctr Int Hlth, Perth, WA, Australia
来源
NEW ENGLAND JOURNAL OF MEDICINE | 2002年 / 347卷 / 23期
关键词
D O I
10.1056/NEJMoa021309
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The global initiative to eradicate bancroftian filariasis currently relies on mass treatment with four to six annual doses of antifilarial drugs. The goal is to reduce the reservoir of microfilariae in the blood to a level that is insufficient to maintain transmission by the mosquito vector. Methods: In nearly 2500 residents of Papua New Guinea, we prospectively assessed the effects of four annual treatments with a single dose of diethylcarbamazine plus ivermectin or diethylcarbamazine alone on the incidence of microfilariae-positive infections, the severity of lymphatic disease, and the rate of transmission of Wuchereria bancrofti by mosquitoes. Random assignment to treatment regimens was carried out according to the village of residence, and villages were categorized as having moderate or high rates of transmission. Results: The four annual treatments with either drug regimen were taken by 77 to 86 percent of the members of the population who were at least five years old; treatments were well tolerated. The proportion with microfilariae-positive infections decreased by 86 to 98 percent, with a greater reduction in areas with a moderate rate of transmission than in those with a high rate. The respective aggregate frequencies of hydrocele and leg lymphedema were 15 percent and 5 percent before the trial began, and 5 percent (P<0.001) and 4 percent (P=0.04) after five years. Hydrocele and leg lymphedema were eliminated in 87 percent and 69 percent, respectively, of those who had these conditions at the outset. The rate of transmission by mosquitoes decreased substantially, and new microfilariae-positive infections in children were almost completely prevented over the five-year study period. Conclusions: Annual mass treatment with drugs such as diethylcarbamazine can virtually eliminate the reservoir of microfilariae and greatly reduce the frequency of clinical lymphatic abnormalities due to bancroftian filariasis. Eradication may be possible in areas with moderate rates of transmission, but longer periods of treatment or additional control measures may be necessary in areas with high rates of transmission.
引用
收藏
页码:1841 / 1848
页数:8
相关论文
共 50 条
  • [31] COMMUNITY RANDOMIZED SAFETY TRIAL OF TRIPLE- DRUG MASS DRUG ADMINISTRATION FOR LYMPHATIC FILARIASIS IN PAPUA NEW GUINEA
    Tavul, Livingstone
    Howard, Samuel
    Laman, Moses
    Kumai, Steven
    Samuel, Anna
    Kotty, Bethuel
    Lorry, Lina
    Makita, Leo
    Yohogu, Mary
    John, Lucy
    Bieb, Sibauk
    Wangi, James
    Siba, Peter
    Bogus, Joshua
    O'Brian, Katiuscia
    Kazura, James
    Weil, Gary J.
    Tisch, Daniel
    King, Christopher L.
    Robinson, Leanne J.
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2017, 97 (05): : 239 - 239
  • [32] MALARIA AND FILARIASIS IN THE OK TEDI REGION OF THE STAR MOUNTAINS, PAPUA-NEW-GUINEA
    CATTANI, J
    TAUFA, T
    ANDERSON, W
    LOURIE, J
    PAPUA NEW GUINEA MEDICAL JOURNAL, 1983, 26 (02) : 122 - 126
  • [33] THE TREATMENT OF LEPROSY IN PAPUA-NEW-GUINEA
    REE, GH
    PAPUA NEW GUINEA MEDICAL JOURNAL, 1982, 25 (03) : 142 - 142
  • [34] Impact of mass drug administration with ivermectin, diethylcarbamazine, and albendazole for lymphatic filariasis on hookworm and Strongyloides stercoralis infections in Papua New Guinea
    Ramos, Jannet A. Tobon
    Maure, Tobias
    Carias, Lenore
    Lew, Daphne
    Goss, Charles
    Samuel, Anna
    Tavul, Livingstone
    Fischer, Peter U.
    Weil, Gary J.
    Laman, Moses
    Robinson, Leanne J.
    Pomat, William
    King, Christopher L.
    PLOS NEGLECTED TROPICAL DISEASES, 2025, 19 (03):
  • [35] RENEWED MASS DRUG ADMINISTRATION'S IMPACT ON LYMPHATIC FILARIASIS IN A POPULATION WITH LONG LASTING INSECTICIDAL BEDNETS IN PAPUA NEW GUINEA
    Tisch, Daniel J.
    Mancuso, Brooke
    Cheng, Yao-Chieh
    Satofan, Samson
    Suamani, James
    Pomat, Willie
    King, Christopher L.
    Kazura, James W.
    Zimmerman, Peter A.
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2017, 97 (05): : 7 - 8
  • [36] AUSTRALIA AND PAPUA-NEW-GUINEA - PAPUA-NEW-GUINEA
    HEGARTY, DW
    AUSTRALIAN JOURNAL OF POLITICS AND HISTORY, 1979, 25 (01): : 106 - 111
  • [37] Albenclazole for mass drug administration to eliminate lymphatic filariasis
    Sabesan, Shanmugavelu
    LANCET INFECTIOUS DISEASES, 2006, 6 (11): : 684 - 685
  • [38] Mass drug administration to eliminate lymphatic filariasis in India
    Ramaiah, KD
    Das, PK
    TRENDS IN PARASITOLOGY, 2004, 20 (11) : 499 - 502
  • [39] A MARK RECAPTURE EXPERIMENT WITH THE FILARIASIS VECTOR ANOPHELES-PUNCTULATUS IN PAPUA-NEW-GUINEA
    CHARLWOOD, JD
    BRYAN, JH
    ANNALS OF TROPICAL MEDICINE AND PARASITOLOGY, 1987, 81 (04): : 429 - 436
  • [40] LONG-TERM IMPACT OF REPEATED MDA ON LYMPHATIC FILARIASIS DISEASE IN PAPUA NEW GUINEA
    Kazura, James W.
    Thomsen, Edward
    Baea, Manasseh
    Zimmerman, Peter A.
    King, Christopher L.
    Siba, Peter
    Tisch, Daniel J.
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2010, 83 (05): : 20 - 20